NCT04688164View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

November 1, 2022

Study Completion Date

November 10, 2022

Conditions
Major Depressive Disorder
Interventions
DRUG

REL-1017

REL-1017 tablet

DRUG

Placebo

Placebo tablet

Trial Locations (11)

10128

Relmada Site, New York

30030

Relmada Site, Decatur

32905

Relmada Site, Palm Bay

33166

Relmada Site, Miami Springs

33175

Relmada Site, Miami

45215

Relmada Site, Cincinnati

60634

Relmada Site, Chicago

63368

Relmada Site, O'Fallon

78737

Relmada Site, Austin

02116

Relmada Site, Boston

02472

Relmada Site, Watertown

All Listed Sponsors
lead

Relmada Therapeutics, Inc.

INDUSTRY

NCT04688164 - A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) | Biotech Hunter | Biotech Hunter